Journal of Cancer Research and Clinical Oncology

, Volume 131, Issue 2, pp 73–79

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index

  • Hideko Goto
  • Hisashi Tsurumi
  • Masao Takemura
  • Yoriko Ino-Shimomura
  • Senji Kasahara
  • Michio Sawada
  • Toshiki Yamada
  • Takeshi Hara
  • Kenji Fukuno
  • Naoe Goto
  • Masataka Okuno
  • Tsuyoshi Takami
  • Mitsuru Seishima
  • Hisataka Moriwaki
Original Paper

DOI: 10.1007/s00432-004-0600-9

Cite this article as:
Goto, H., Tsurumi, H., Takemura, M. et al. J Cancer Res Clin Oncol (2005) 131: 73. doi:10.1007/s00432-004-0600-9

Abstract

Purpose

The aim of the present study was to assess the prognostic significance of serum soluble interleukin-2 receptor (sIL-2R) in aggressive non-Hodgkin’s lymphoma (NHL).

Methods

One hundred and thirteen consecutive patients with previously untreated aggressive NHL (diffuse large B-cell lymphoma, 96; peripheral T-cell lymphoma, 17) prospectively participated in this study between 1995 and 2001. The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.

Results

A high serum sIL-2R level (2,000 U/ml and over) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5-year, 24%) than those with low sIL-2R (under 2,000 U/ml) (74%) (P<0.01). Multivariate analysis employing sIL-2R levels and conventional prognostic factors demonstrated that high sIL-2R, presence of B-symptoms, and advanced age (60 years and older) were significantly unfavorable variables for overall survival. In addition, we attempted to use sIL-2R in combination with the International Prognostic Index (IPI). The patients in the high (H) risk group and those with high sIL-2R in the low-intermediate (LI)/high-intermediate (HI) risk group had significantly lower survival rates than the patients in the low (L) risk group and those with low sIL-2R in the LI/HI risk group (P<0.001).

Conclusion

The results suggest that a high serum sIL-2R level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment when used in combination with the IPI.

Keywords

Soluble interleukin-2 receptor (sIL-2R) International Prognostic Index (IPI) Prognostic factor Non-Hodgkin’s lymphoma 

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Hideko Goto
    • 1
    • 1
  • Hisashi Tsurumi
    • 1
  • Masao Takemura
    • 2
  • Yoriko Ino-Shimomura
    • 1
  • Senji Kasahara
    • 1
  • Michio Sawada
    • 1
  • Toshiki Yamada
    • 1
  • Takeshi Hara
    • 1
  • Kenji Fukuno
    • 1
  • Naoe Goto
    • 1
    • 1
  • Masataka Okuno
    • 1
  • Tsuyoshi Takami
    • 3
  • Mitsuru Seishima
    • 2
  • Hisataka Moriwaki
    • 1
  1. 1.First Department of Internal MedicineGifu University Graduate School of MedicineGifuJapan
  2. 2.Department of Clinical LaboratoryGifu University Graduate School of MedicineGifuJapan
  3. 3.Department of Cellular PathologyGifu University Graduate School of MedicineGifuJapan

Personalised recommendations